Product Details
| Product Name:
Sorivudine |
CAS No.:
77181-69-2 |
| Purity:
97.33% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | Sorivudine |
| Description | Sorivudine (BV-araU) has antiviral activity against several viruses including varicella zoster virus, herpes simplex type 1 virus, and Epstein-Barr virus by interfering with viral DNA synthesis. |
| In vitro | Sorivudine inhibits strains of HSV-1 and HSV-2 (ID50s (50% inhibitory dose): 0.39 and 0.67 μM, respectively). Sorivudine has antiviral activity against several viruses including varicella-zoster virus, herpes simplex type 1 virus, and Epstein-Barr virus. Sorivudine has in vitro inhibitory activity against the varicella-zoster virus at concentrations of 00001-0.004 mg/ml. These concentrations are over 1000-fold lower than those which are required for the inhibition of VZV replication by acyclovir 3 Sorivudine also inhibits HSV-I replication at concentrations ranging from 0.03-0.1 mg/ml [1][2]. |
| In vivo | Sorivudine has been evaluated in the treatment of HSV-l encephalitis when administered orally to mice. The survival of treated mice is prolonged at dosages in excess of 12.5 mg/kg. A significant decrease in mortality was achieved as well with doses in excess of 50 mg/kg. Sorivudine therapy at dosages as low as 20 mg/kg per day given intramuscularly or 100 mg/kg per day administered orally completely protected against viremia and mortality. There was no evidence of neurotoxicity or abnormalities in hematology or clinical chemistries. Doses as low as 0.2 mg/kg per day were effective; however, breakthrough viremia was noted at lower dosages [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 125 mg/mL (358.03 mM), Sonication is recommended.
|
| Keywords | nucleoside | antiviral | inhibit | antimetabolite | Sorivudine | Epstein-Barr | pyrimidine | virus | zoster | oral | varicella | Inhibitor | herpes | DNA/RNA Synthesis | simplex | type |
| Inhibitors Related | Rifampicin | 5-Fluorouracil | Ribavirin | Guanidine hydrochloride | 2,4-D | Resveratrol | Acyclovir | Thymidine | Temozolomide | Folic acid |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | Pediatric Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Orally Active Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:78110-38-0
$35.00 / 25mg
-
CAS:2250404-95-4
$74.00 / 1mg
-
CAS:13161-75-6
$60.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States